Polyphosphazene immunoadjuvants: Historical perspective and recent advances
© 2020 Elsevier B.V. The development of successful vaccines has been increasingly reliant on the use of immunoadjuvants - additives, which can enhance and modulate immune responses to vaccine antigens. Immunoadjuvants of the polyphosphazene family encompass synthetic biodegradable macromolecules, wh...
| প্রধান লেখক: | , |
|---|---|
| অন্যান্য লেখক: | |
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | English |
| প্রকাশিত: |
Elsevier BV
2022
|
| অনলাইন ব্যবহার করুন: | https://hdl.handle.net/1721.1/139665 |
| _version_ | 1826209107316572160 |
|---|---|
| author | Andrianov, Alexander K Langer, Robert |
| author2 | Koch Institute for Integrative Cancer Research at MIT |
| author_facet | Koch Institute for Integrative Cancer Research at MIT Andrianov, Alexander K Langer, Robert |
| author_sort | Andrianov, Alexander K |
| collection | MIT |
| description | © 2020 Elsevier B.V. The development of successful vaccines has been increasingly reliant on the use of immunoadjuvants - additives, which can enhance and modulate immune responses to vaccine antigens. Immunoadjuvants of the polyphosphazene family encompass synthetic biodegradable macromolecules, which attain in vivo activity via antigen delivery and immunostimulation mechanisms. Over the last decades, the technology has witnessed evolvement of next generation members, expansion to include various antigens and routes of administration, and progression to clinical phase. This was accompanied by gaining important insights into the mechanism of action and the development of a novel class of virus-mimicking nano-assemblies for antigen delivery. The present review evaluates in vitro and in vivo data generated to date in the context of latest advances in understanding the primary function and biophysical behavior of these macromolecules. It also provides an overview of relevant synthetic and characterization methods, macromolecular biodegradation pathways, and polyphosphazene-based multi-component, nanoparticulate, and microfabricated formulations. |
| first_indexed | 2024-09-23T14:17:40Z |
| format | Article |
| id | mit-1721.1/139665 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T14:17:40Z |
| publishDate | 2022 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/1396652023-04-13T14:49:24Z Polyphosphazene immunoadjuvants: Historical perspective and recent advances Andrianov, Alexander K Langer, Robert Koch Institute for Integrative Cancer Research at MIT Massachusetts Institute of Technology. Department of Chemical Engineering © 2020 Elsevier B.V. The development of successful vaccines has been increasingly reliant on the use of immunoadjuvants - additives, which can enhance and modulate immune responses to vaccine antigens. Immunoadjuvants of the polyphosphazene family encompass synthetic biodegradable macromolecules, which attain in vivo activity via antigen delivery and immunostimulation mechanisms. Over the last decades, the technology has witnessed evolvement of next generation members, expansion to include various antigens and routes of administration, and progression to clinical phase. This was accompanied by gaining important insights into the mechanism of action and the development of a novel class of virus-mimicking nano-assemblies for antigen delivery. The present review evaluates in vitro and in vivo data generated to date in the context of latest advances in understanding the primary function and biophysical behavior of these macromolecules. It also provides an overview of relevant synthetic and characterization methods, macromolecular biodegradation pathways, and polyphosphazene-based multi-component, nanoparticulate, and microfabricated formulations. 2022-01-24T16:10:51Z 2022-01-24T16:10:51Z 2021 2022-01-24T15:52:53Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/139665 Andrianov, Alexander K and Langer, Robert. 2021. "Polyphosphazene immunoadjuvants: Historical perspective and recent advances." Journal of Controlled Release, 329. en 10.1016/J.JCONREL.2020.12.001 Journal of Controlled Release Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier BV PMC |
| spellingShingle | Andrianov, Alexander K Langer, Robert Polyphosphazene immunoadjuvants: Historical perspective and recent advances |
| title | Polyphosphazene immunoadjuvants: Historical perspective and recent advances |
| title_full | Polyphosphazene immunoadjuvants: Historical perspective and recent advances |
| title_fullStr | Polyphosphazene immunoadjuvants: Historical perspective and recent advances |
| title_full_unstemmed | Polyphosphazene immunoadjuvants: Historical perspective and recent advances |
| title_short | Polyphosphazene immunoadjuvants: Historical perspective and recent advances |
| title_sort | polyphosphazene immunoadjuvants historical perspective and recent advances |
| url | https://hdl.handle.net/1721.1/139665 |
| work_keys_str_mv | AT andrianovalexanderk polyphosphazeneimmunoadjuvantshistoricalperspectiveandrecentadvances AT langerrobert polyphosphazeneimmunoadjuvantshistoricalperspectiveandrecentadvances |